Literature DB >> 23429306

Adverse Events With the Use of rhBMP-2 in Thoracolumbar and Lumbar Spine Fusions: A 9-Year Institutional Analysis.

Daniel Lubelski1, Kalil G Abdullah, Michael P Steinmetz, Matthew D Alvin, Amy S Nowacki, Srita Chakka, Edward C Benzel, Thomas E Mroz.   

Abstract

STUDY
DESIGN: Retrospective chart review.
OBJECTIVE: To describe the adverse outcomes associated with the use of rhBMP-2 in thoracolumbar and lumbar fusions. SUMMARY OF BACKGROUND DATA: rhBMP-2 has been increasingly used in spinal fusions over the past decade. Early studies reported that the use of rhBMP-2 is associated with decreased operative time, blood loss, and pain scores, as well as improved fusion rates. Recent investigations have shown rhBMP-2 to be associated with various complications occurring at incidences ranging from 0% to 100%.
METHODS: Using the institutional electronic medical records, we retrospectively reviewed all patients between January 2002 and September 2010 that underwent thoracolumbar and lumbar spine fusion with BMP. Patient demographics, operative, and outcome/complication information was collected.
RESULTS: A total of 547 patient charts were reviewed with a mean follow-up time of 17 months. Mean age was 58 years. Forty-one percent of patients had undergone previous spine surgery. Thirty-nine percent of patients had a PLIF/TLIF, 29% underwent a PLF, and 20% an ALIF. No relevant differences in the patient characteristics and complications were identified between the various surgical approaches. For all approaches, having undergone a previous spine surgery was associated with increased incidence of radiculitis, reoperation, and pseudoarthrosis (P=0.005, 0.0008, 0.05, respectively) as compared with those without previous spine surgery. Being a current smoker at the time of operation was associated with increased rate of radiculitis (P=0.03) as compared with nonsmokers.
CONCLUSIONS: The use of rhBMP-2, in this study, had an incidence of radiculitis, pseudoarthrosis, and reoperation that was similar to the rates in historical controls without rhBMP-2. Complications do not differ by surgical approach, but are more likely in current smokers and those undergoing revision surgery. A prospective study is warranted to further delineate the adverse event profile of rhBMP-2 and the variables that are likely to affect it (ie, type of surgery, carrier, and dose).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 23429306     DOI: 10.1097/BSD.0b013e318287f2e2

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  5 in total

1.  Novel bone grafting technique in stand-alone ALIF procedure combining allograft and autograft ('Northumbria Technique')-Fusion rate and functional outcomes in 100 consecutive patients.

Authors:  Ata George Kasis; Cyrus Jensen; Rahul Dharmadhikari; Benjamin Ross Emmerson; Matthew Mawdsley
Journal:  Eur Spine J       Date:  2021-02-15       Impact factor: 3.134

2.  Postoperative Cyst Associated with Bone Morphogenetic Protein Use in Posterior and Transforaminal Lumbar Interbody Fusion Managed Conservatively: Report of Two Cases.

Authors:  Eli M Baron; Diana M Mejía; Doniel Drazin; Neel Anand
Journal:  Cureus       Date:  2016-02-07

3.  Does Recombinant Human Bone Morphogenic Protein 2 Affect Perioperative Blood Loss after Lumbar and Thoracic Spinal Fusion?

Authors:  Nathan Wanderman; Bayard Carlson; William Robinson; Mohamad Bydon; Michael Yaszemski; Paul Huddleston; Brett Freedman
Journal:  Asian Spine J       Date:  2018-09-10

4.  Image Guidance-Assisted Decompression and Removal of Heterotopic Ossification Following the Use of Recombinant Human Bone Morphogenetic Protein-2 in Transforaminal Lumbar Interbody Fusion.

Authors:  Julie L Chan; Robert A Ravinsky; J Patrick Johnson; Eli M Baron
Journal:  Cureus       Date:  2021-11-30

5.  Maresin 1 resolves aged-associated macrophage inflammation to improve bone regeneration.

Authors:  Rong Huang; Linda Vi; Xiaohua Zong; Gurpreet S Baht
Journal:  FASEB J       Date:  2020-08-14       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.